Alnylam Pharmaceuticals (ALNY) News Today $273.15 -1.31 (-0.48%) (As of 09/18/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period TD Cowen maintains Alnylam stock at Buy rating with steady price targetSeptember 19 at 12:32 AM | investing.comE Fund Management Co. Ltd. Has $1.20 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)E Fund Management Co. Ltd. increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 75.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,926 shares of the biopharmaceutical company's stockSeptember 18 at 6:12 AM | marketbeat.comAlnylam Pharma (ALNY) Receives a Buy from Bank of America SecuritiesSeptember 16 at 7:39 PM | markets.businessinsider.comTD Cowen Sticks to Their Buy Rating for Alnylam Pharma (ALNY)September 16 at 7:39 PM | markets.businessinsider.comInnate Pharma (IPHA) Receives a Buy from Evercore ISISeptember 16 at 5:08 AM | markets.businessinsider.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Federated Hermes Inc.Federated Hermes Inc. lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 37.6% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 92,608 shares of the biopharmacSeptember 16 at 5:03 AM | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Sees Significant Decline in Short InterestSeptember 16 at 3:01 AM | americanbankingnews.comInhibrx: The Biotech Spinoff Poised For Big GainsSeptember 16 at 12:07 AM | forbes.comAlnylam Pharmaceuticals, Inc. (ALNY): Hedge Funds Are Bullish on This Aggressive Growth StockSeptember 15, 2024 | msn.comForsta AP Fonden Has $6.12 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Forsta AP Fonden reduced its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 63.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,200 shares of the biopharmaceutical company's sSeptember 15, 2024 | marketbeat.comThree Stocks That Might Be Undervalued In September 2024September 14, 2024 | uk.finance.yahoo.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by State of New Jersey Common Pension Fund DState of New Jersey Common Pension Fund D cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 33.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 48,458 shares of the biopharmaceutical company's stock after selling 24,801September 14, 2024 | marketbeat.comAndra AP fonden Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Andra AP fonden purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,100 shares of the biopharmaceutical coSeptember 13, 2024 | marketbeat.comHealth Care Up on Cyclical Bias -- Health Care RoundupSeptember 13, 2024 | marketwatch.comAlnylam Stock Soars 65%: Find Out What's Behind the GainsSeptember 12, 2024 | msn.comAlnylam Stock Soars 65%: Find Out What’s Behind the GainsAlnylam Pharmaceutical is on the move. In early to mid-2025, the FDA is expected to approve expanded use of a key drug.September 12, 2024 | marketbeat.comAmerican Century Companies Inc. Lowers Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)American Century Companies Inc. decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 1.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,354,169 shares of the biopharmaceutical companySeptember 12, 2024 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Acadian Asset Management LLCAcadian Asset Management LLC raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2,148.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 37,310 shares of the biopharmaceutical company's stock afteSeptember 11, 2024 | marketbeat.comCantor Fitzgerald Reiterates Neutral Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)September 11, 2024 | americanbankingnews.comRoyal London Asset Management Ltd. Sells 44,524 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Royal London Asset Management Ltd. lessened its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 13.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 282,345 shares of the biopharmaceutical comSeptember 10, 2024 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Given "Neutral" Rating at Cantor FitzgeraldCantor Fitzgerald reiterated a "neutral" rating and issued a $220.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday.September 9, 2024 | marketbeat.comEFG Asset Management Americas Corp. Increases Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)EFG Asset Management Americas Corp. boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 56.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,992 shares ofSeptember 7, 2024 | marketbeat.comANTIPODES PARTNERS Ltd Grows Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)ANTIPODES PARTNERS Ltd boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 16.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 238,749 shares of the biopharmaceutical company's stock after buying an additiSeptember 6, 2024 | marketbeat.comAlnylam Pharma’s Vutrisiran Garners Strong Buy Rating Amidst Positive ATTR-CM Treatment ProspectsSeptember 5, 2024 | markets.businessinsider.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Reaffirmed by Royal Bank of CanadaRoyal Bank of Canada reiterated an "outperform" rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday.September 4, 2024 | marketbeat.comBank of America Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $307.00Bank of America lifted their target price on shares of Alnylam Pharmaceuticals from $295.00 to $307.00 and gave the stock a "buy" rating in a research note on Wednesday.September 4, 2024 | marketbeat.comMaintaining Hold on Alnylam Pharma: Vutrisiran’s Promise in ATTR-CM Treatment Balanced by Valuation ConcernsSeptember 3, 2024 | markets.businessinsider.comStrong Buy Rating for Alnylam Pharma Backed by Positive Clinical Data and Robust Commercial StrategySeptember 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alnylam Pharma Amid Strong Financial Prospects and Market PositioningSeptember 3, 2024 | markets.businessinsider.comAlnylam Pharmaceuticals Insiders Sold US$5.0m Of Shares Suggesting HesitancySeptember 2, 2024 | finance.yahoo.comBuy Rating for Alnylam Pharma Backed by Positive HELIOS-B Study Results and Strong Commercial Prospects for VutrisiranSeptember 2, 2024 | markets.businessinsider.comVan ECK Associates Corp Increases Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Van ECK Associates Corp lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 5.2% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 60,938 shares of the biopharmaceutical company's sSeptember 2, 2024 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Average Rating of "Moderate Buy" by AnalystsShares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty-four research firms that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommenSeptember 2, 2024 | marketbeat.comiA Global Asset Management Inc. Boosts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)iA Global Asset Management Inc. increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 30.4% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,122 shares of the biopharmaceutical company's stock after buying anSeptember 1, 2024 | marketbeat.comStrong Buy on Alnylam Pharmaceuticals Amidst ATTR-CM Treatment Potential and Undervalued Stock PriceAugust 31, 2024 | markets.businessinsider.comESC Congress: Amvuttra data signals positive prospects in cardiomyopathy for AlnylamAugust 31, 2024 | finance.yahoo.comSumitomo Mitsui DS Asset Management Company Ltd Has $2.94 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 27.6% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 12,114 shares of theAugust 31, 2024 | marketbeat.comAlnylam’s stock drops on new heart disease drug dataAugust 30, 2024 | bizjournals.comWhy IBD 50's Alnylam Just Reversed Its 50% Gain — And BridgeBio SurgedAugust 30, 2024 | msn.comAlnylam tumbles, BridgeBio gains after heart drug dataAugust 30, 2024 | msn.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Rating Reiterated by HC WainwrightHC Wainwright reissued a "buy" rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday.August 30, 2024 | marketbeat.comAlnylam: HELIOS-B Success Priced In AlreadyAugust 30, 2024 | seekingalpha.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap Down to $287.01Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap Down to $287.01August 30, 2024 | marketbeat.comS&P 500 Futures Climb in Premarket Trading; Elastic, Alnylam Pharmaceuticals LagAugust 30, 2024 | marketwatch.comAlnylam Pharma Down 11% In Pre-market Despite Positive Data From HELIOS-B Phase 3 StudyAugust 30, 2024 | markets.businessinsider.comAlnylam Falls as Heart Disease Drug Data Disappoint InvestorsAugust 30, 2024 | bloomberg.comAlnylam Stock Falls on Positive but Disappointing Study Results for Heart DrugAugust 30, 2024 | wsj.comAlnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart MusclesAugust 30, 2024 | msn.comAlnylam shares slide after heart drug data fails to impress investorsAugust 30, 2024 | reuters.comBreakwater Capital Group Acquires Shares of 1,025 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Breakwater Capital Group bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 1,025 shares of the biopharmaceutical company's stock, valued at approxAugust 28, 2024 | marketbeat.com Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Unlock the Secret to Easy Wins with Iron Condors (Ad)Discover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consistently without needing a large account or watching the market all day. Our free report, The Top 10 Stocks for Iron Condor Trades, reveals exactly how to set up winning trades with minimal downside. Download Your FREE Iron Condor Guide Now ALNY Media Mentions By Week ALNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALNY News Sentiment▼0.790.65▲Average Medical News Sentiment ALNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALNY Articles This Week▼189▲ALNY Articles Average Week Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BeiGene News Royalty Pharma News Sarepta Therapeutics News Catalent News Elanco Animal Health News Regeneron Pharmaceuticals News Vertex Pharmaceuticals News Gilead Sciences News Biogen News BioMarin Pharmaceutical News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALNY) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredIt’s over.We found a tiny company which provides the backbone for the entire $15.7 trillion AI industry... It's used ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
